Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Controlled Trial Examining the Effectiveness of the New Recovery-oriented Creative Writing Group Intervention REWRITALIZE for People With Schizophrenia Spectrum Disorders

NCT06251908 is registered in ClinicalTrials.gov with Amager Hospital as lead sponsor.

NCT NCT06251908
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06251908 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Controlled Trial Examining the Effectiveness of the New Recovery-oriented Creative Writing Group Intervention REWRITALIZE for People With Schizophrenia Spectrum Disorders
Lead sponsor
Amager Hospital
Phase
Not applicable
Overall status
Active, not recruiting
Start date
February 12, 2024
Completion date
April 30, 2027
Enrollment
300 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar disorder, personality disorder, borderline, psychosis, ptsd, schizophreniform disorders, severe depression